STAT Plus: Sanofi pulls Zantac from the U.S., joining a growing list of companies recalling heartburn meds
One month after numerous companies began extensive recalls of their heartburn drugs because traces of a possible carcinogen were found in certain medicines, Sanofi (SNY) is now joining the list and recalling Zantac from the U.S. and Canada.
The move comes as regulators attempt to understand why NDMA, an organic chemical that was once used to make rocket fuel and is an unintended byproduct of certain chemical reactions, was found in some ranitidine medicines. These drugs, which are histamine-2 blockers that decrease the amount of acid created by the stomach, are sold both over the counter and by prescription.
Continue to STAT Plus to read the full story…
